Liu Ye

2011,, 、 、. Joslin.: 、. 、 、 、,. 、Diabetes Obes Metab、Sex Med 2020, 2016,, (5/6) 2016, 20,: 1. Ye Liu, Ran Lu, Junhong Wang, Qin Cheng, Ruitao Zhang, Shuisheng Zhang, Yunyi Le, Haining Wang, Wenhua Xiao, Hongwei Gao, Lin Zeng, Tianpei Hong*. Diabetes, even newly defined by HbA1c testing, is associated with an increased risk of in-hospital death in adults with COVID-19. BMC Endocr Disord. 2021; 21(1):56. 2. Ye Liu, Qin Cheng, Junhong Wang, Shu Li, Ci Tian, Yuxuan Li, Wenhui Zhang, Ning Shen, Jie Qiao*. Family companion between patients with coronavirus disease 2019: a retrospective observational study. Chin Med J (Engl). 2020, 133(20):2507-2509. 3. Wang H, Liu Y (Co-first author), Tian Q, Yang J, Lu R, Zhan S, Haukka J, Hong T*. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018, 20(4):910-920. 4. Liu Y, Tian Q, Yang J, Wang H, Hong T*. No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials. Diabetes Metab Res Rev. 2018, 34(8):e3061. 5. Liu Y, Hong T*. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diabetes Obes Metab, 2014, 16(2):111-117. 6. Wang L, Liu Y (Co-first author), Yang J, Zhao HJ, Ke J, Tian Q, Zhang L, Wen JH, Wei R*, Hong TP*. Liraglutide upregulates PC1-mediated Proinsulin processing in pancreatic cells via a PKA-dependent pathway. Endocrinology. 2014, 155(10):3817-3828. 7. Liu Y, Rui Wei, Tianpei Hong*. Potential Roles and Mechanisms of Glucagon-like Peptide-1 in Non-alcoholic Fatty Liver Disease. World J Gastroenterol. 2014, 20(27): 9090-9097. 8., *,.., 2022, 102(6): 445-448. 9.,,,,, *.., 2020,12 (10): 814-818. DOI: 10.3760/cma.j.cn115791-20200120-0002910. 10., *,,. 1: ？, 31(5): 386-389, 2015. 11., *. 2., 95 (44): 3565-3567, 2015. 《 》、《 》